an Open-Label, Randomized, Controlled, Crossover Study to assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in adult Smokers.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Goldenson (2021)
Differences in Switching Away From Smoking Among Adult Smokers Using JUUL Products in Regions With Different Maximum Nicotine Concentrations: North America and the United Kingdom.
Population Clinical
Likelihood Of Use
Former Smokers Switching To ENDS
Goldenson (2021)
Switching away from Cigarettes across 12 Months among Adult Smokers Purchasing the JUUL System.
Population Clinical
Likelihood Of Use
Former Smokers Switching To ENDS
Goldenson (2021)
Differences in switching away from cigarettes and JUUL use characteristics among adult menthol and nonmenthol smokers who purchased the JUUL System.
Population Clinical
Likelihood Of Use
Former Smokers Switching To ENDS
Goldenson (2022)
association Between E-Cigarette Use and Visual Impairment in the United States.
Individual Clinical
Safety
Adverse Effects
Golla (2022)
Determination of nicotine content in e-cigarettes and e-liquid refills utilizing hPLC methods.
Nonclinical
Chemical
Methods
Golob (2019)
Comprehensive characterization of volatile and semi-volatile compounds in e-liquids for electronic cigarette using gas chromatography accurate mass spectrometry.
Nonclinical
Chemical
Analysis
Golpe (2023)
Association Between Electronic Cigarette Use and Smoking Reduction in France.
Population Clinical
Cessation
Tobacco
Gomajee (2019)
E-cigarettes: Effects in phagocytosis and cytokines response against Mycobacterium tuberculosis.
Nonclinical
Immunotoxicity
In Vitro
Gómez (2020)
Electronic Cigarettes are a Source of Thirdhand Exposure to Nicotine
Individual Clinical
Respiratory Toxicity
Secondary & Tertiary
Exposure
Goniewicz (2014)